Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — April 2025

Genmab — April 2025

Planlagt Fastgjort Låst Flyttet Genmab
294 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #83

    Very interesting and it will give Gmab somewaht of a competitive advantage, having aldready onboarded this system. Great to se that Gmab is living out their AI ambitions and increasing efficiency in the lab.

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #84

      https://www.dnb.no/seg-fundamental/fundamentalweb/inst/GetReport.aspx?file=CMP4_254575.pdf&uid=1154&auth=2jMoUXPS1%2FJy8ZNikSg5XXKm0kY%3D&pwd=&popup=n I don't think this Research report from DNB Markets from last month was posted yet

      1 Reply Last reply
      0
      • L Offline
        L Offline
        lahn1
        wrote on sidst redigeret af
        #85

        Thx EL, funny to see how low they set peaksales for acasunlimab and high on Gen1042, btw first est I have seen on Gen1042. Even Mim8 included, nice!

        1 Reply Last reply
        0
        • R Offline
          R Offline
          Raun
          wrote on sidst redigeret af
          #86

          Er det kun mig der ikke kan åbneDNB reporten?

          1 Reply Last reply
          0
          • G Offline
            G Offline
            gentogen
            wrote on sidst redigeret af
            #87

            Når jeg klikker, downloades en pdf med rapporten

            1 Reply Last reply
            0
            • L Offline
              L Offline
              lahn1
              wrote on sidst redigeret af
              #88

              Den ligger også i debatten hvis linket ikke virker

              1 Reply Last reply
              0
              • concilladoC Offline
                concilladoC Offline
                concillado
                wrote on sidst redigeret af
                #89

                Så er der sgu snart aktier til en tusse! 🙂

                1 Reply Last reply
                0
                • W Offline
                  W Offline
                  w
                  wrote on sidst redigeret af
                  #90

                  PE under 10

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #91

                    European Commission approves Johnson & Johnson’s subcutaneous DARZALEX® (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility -CEPHEUS
                    https://www.globenewswire.com/news-release/2025/04/07/3056498/0/en/European-Commission-approves-Johnson-Johnson-s-subcutaneous-DARZALEX-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regard.html

                    1 Reply Last reply
                    0
                    • R Offline
                      R Offline
                      Raffles
                      wrote on sidst redigeret af
                      #92

                      Vedr. DNB Markets Research Report: De har launch af Acasunlimab i 2026. Er det ikke lige tidligt nok? Jeg forventer launch i 2027/2028. Tilsvarende har de launch af Mim8 i 2025 - har Novo indgivet ansøgning endnu??

                      1 Reply Last reply
                      0
                      • K Offline
                        K Offline
                        kkjoel
                        wrote on sidst redigeret af
                        #93

                        Nej, Raffles -
                        disse studsede jeg osse over. Novo indgiver ansøgning i løbet af 2025, men har ikke gjort det end nu.. så indtægter blir tidligst fra 2026.

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #94

                          Transactions In Connection with Share Buy-back Program
                          Apr 7, 2025 https://ir.genmab.com/news-releases/news-release-details/transactions-connection-share-buy-back-program-49

                          1 Reply Last reply
                          0
                          • R Offline
                            R Offline
                            Raffles
                            wrote on sidst redigeret af
                            #95

                            Vedr. et eventuelt fremtidigt salg kan samme salgsstyrke vel stå for salget at Tivdak og Rina-S (Cervial, Ovarian og Endometrial cancer). Men kan samme salgsstyrke også stå for et evt. salg af Acasunlimab i NSCLC eller kræver det en anden salgsstyrke? Nogen med kendskab til Pharmasalg der kan bidrage?

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              Plimsoller
                              wrote on sidst redigeret af
                              #96

                              Hvis de fastholder det nuværende tempo mht. aktietilbagekøb, så er de jo færdige midt i maj.

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #97

                                European Commission approves subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer https://www.globenewswire.com/news-release/2025/04/07/3056770/0/en/European-Commission-approves-subcutaneous-RYBREVANT-amivantamab-for-the-treatment-of-patients-with-advanced-EGFR-mutated-non-small-cell-lung-cancer.html

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  lahn1
                                  wrote on sidst redigeret af
                                  #98

                                  THX EL very nice, looks like a double approval. Rybrevant SC - CHECK

                                  1 Reply Last reply
                                  0
                                  • Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktør
                                    wrote on sidst redigeret af
                                    #99

                                    Godmorgen

                                    1 Reply Last reply
                                    0
                                    • L Offline
                                      L Offline
                                      LP90
                                      wrote on sidst redigeret af
                                      #100

                                      Godmorgen

                                      1 Reply Last reply
                                      0
                                      • concilladoC Offline
                                        concilladoC Offline
                                        concillado
                                        wrote on sidst redigeret af
                                        #101

                                        @Plimsoller (kl. 14:55): Tempoet skyldes en i forvejen alt for lav kurs på Genmab, men det giver også supergod mening at opkøbe rigtig meget nu, hvor kursen er yderligere banket i bund pga. Trump-kaoset (og den kommende uundgåelig recession som USA er på vej ind, hvis ikke kursen bliver lagt om).

                                        1 Reply Last reply
                                        0
                                        • J Offline
                                          J Offline
                                          JKY_VH
                                          wrote on sidst redigeret af
                                          #102

                                          Det giver rigtig god mening og hvis de så ville opkøbe for et mia. beløb og ikke et antal stk. ville det være endnu bedre.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper